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Background
ocaine and other amphetamine-like psychos-
timulants have been a significant part of the human phar-
macopoeia for thousands of years.
1,2 However, the
appearance of these substances in Western societies has
been relatively recent,cocaine having debuted as both
a local anesthetic and a psychostimulant in the 19th cen-
tury. Over the course of the next century, it became
increasingly clear that the amphetamine-like psychos-
timulants carried serious abuse liability,as well as pro-
ducing a prominent paranoia-like syndrome among many
individuals who chronically used this class of drugs.
3,4The
abuse liability of these drugs has resulted in sociological
use patterns that have been described as epidemics,such
as the methamphetamine epidemic in Japan in the 1950s,
the cocaine epidemic in the United States in the 1980s,
and the crack cocaine epidemic of the 1990s.
5,6
The high abuse liability of this class of drugs relies on
both pharmacological properties and the sociological
characteristics of how the drugs are introduced into var-
ious societies around the world.This article will not sig-
nificantly address the sociology of psychostimulant abuse,
which involves diverse events ranging from the use of
amphetamines by Japanese soldiers in World War II,to
the formulation of crack as a less expensive version of
cocaine in the United States,to the introduction of pre-
scription formulations to regulate eating habits or to treat
attention deficit-hyperactivity disorder.
5-8 Rather,we will
review the basic pharmacology of amphetamine-like
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Although the pharmacology of amphetamine-like psy-
chostimulants at dopamine transporters is well under-
stood, addiction to this class of drugs has proven diffi-
cult to deal with. The reason for this disconnection is
that while the molecular mechanism of amphetamine
action is critical to reinforce drug use, it is only the first
step in a sequence of widespread neuroplastic events in
brain circuitry. This review outlines the affect of psy-
chostimulants on mesocorticolimbic dopamine projec-
tions that mediate their reinforcing effect, and how this
action ultimately leads to enduring pathological neu-
roplasticity in glutamatergic projections from the pre-
frontal cortex to the nucleus accumbens. Molecular neu-
roadaptations induced by psychostimulant abuse are
described in glutamate neurotransmission, and from this
information potential pharmacotherapeutic targets are
identified, based upon reversing or countermanding
psychostimulant-induced neuroplasticity.   
© 2007, LLS SAS Dialogues Clin Neurosci. 2007;9:389-397.drugs, integrate these molecular mechanisms into the
brain circuitry of reward,and describe how these drugs
are thought to create pathological changes in reward and
learning circuitry.Finally,this knowledge will be amalga-
mated into a vision of future pharmacotherapies for
treating psychostimulant addiction.
Basic pharmacology of amphetamine-like 
psychostimulants
The defining mechanism of action of amphetamine-like
psychostimulants as a class of drugs with high abuse lia-
bility is the ability to bind to dopamine transporters
(DAT).
9,10 Dopamine transporters are a member of a
class of proteins that eliminate monoamines,including
dopamine,from the synaptic cleft after neuronal release.
11
This protein has a high affinity for dopamine relative to
other monoamines,such as norepinephrine or serotonin,
and while all the readily abused psychostimulants bind
to DAT, they may also bind to the other monoamine
transporters with greater or lesser affinity.
9,12 To some
extent,the relative profile of binding by individual drugs
to the different transporter proteins explains different
characteristics of the drugs.Most striking,for example,is
3,4-methylenedioxymethamphetamine (MDMA) which
has a relatively higher affinity for serotonin transporters,
and is thereby a mild hallucinogen and neurotoxic to
serotonin axon terminals,
13,14 while methamphetamine
binds more avidly to DAT,which explains its greater tox-
icity at dopamine terminals,as well as its propensity to
induce paranoid psychosis-like symptoms.
15 While the
binding to other monoamine transporters contributes to
the antidepressant and hallucinogenic characteristics of
some psychostimulants,it is the binding to DAT that pro-
vides the major influence on abuse liability,which is the
focus of this review.
There are two major categories of interaction by ampet-
amine-like psychostimulants with DAT,but in all cases the
end result is to inhibit the elimination of dopamine from
the synapse and thereby increase the quantity and half-life
of synaptic and extrasynaptic dopamine levels.
16,17The first
mechanism is typified by cocaine and methylphenidate
that bind to DAT,but are not transported into the presy-
naptic terminal as surrogate dopamine.Therefore,when
these drugs bind to DAT the increase in extracellular
dopamine relies primarily on normal synaptic release,
which is more amenable to physiological feedback regu-
lation.
18 The second mechanism is typified by ampheta-
mines, and involves not only binding to DAT, but also
translocation into the cell in place of dopamine.
9 In addi-
tion,these drugs enter dopamine synaptic vesicles,where
the fact that these compounds are basically charged
degrades the pH gradient necessary to sequester
dopamine into the vesicle.
19This in turn results in a large
buildup of dopamine in the cytosol,thereby reversing the
direction of DAT to release dopamine into the extracellu-
lar space rather than facilitating its removal.Regardless of
the precise interaction with DAT by individual ampheta-
mine-like psychostimulants,this class of drugs dramatically
elevates extracellular dopamine,and this action is thought
to be the initiating molecular event that reinforces drug-
seeking behaviors,ultimately culminating in addiction.
20,21
How release of dopamine by 
psychostimulants initiates addiction
Dopamine release is physiologically employed to signal
novel,motivationally relevant environmental events.Thus,
when an organism encounters a novel stimulus,whether a
positive stimulus such as a food reward or a negative stim-
ulus such as a stressor,the activity of dopamine cells in the
ventral tegmental area,and dopamine release in axon ter-
minal fields in the prefrontal cortex,nucleus accumbens,
and/or amygdale,are altered.
22-24An important character-
istic of this brain-environment interaction is that the abil-
ity of a given stimulus to increase dopamine cell firing and
release decreases with repeated presentation of the stim-
ulus. However, it can be shown that if a motivationally
neutral stimulus (such as a light or tone) is associated with
the motivational event in such a manner that the neutral
stimulus predicts arrival of the motivational event,the abil-
ity of the motivational stimulus to release dopamine is
transferred to the neutral stimulus.
22,25,26Thus,the neutral
stimulus now causes dopamine release in a manner pre-
dicting arrival of a motivationally relevant event.Based
upon these data, the role for dopamine release in the
mesocorticolimbic brain regions is twofold:(i) to cue the
organism that a novel motivationally relevant event is
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Selected abbreviations and acronyms
AMPA -amino-3-hydroxy-5-methylisoxazole-4-
propionic acid
DAT dopamine transporters
GABA -aminobutyric acid
MDMA 3,4-methylenedioxymethamphetamine
mGluR2/3 metabotropic glutamate receptorsoccurring and that adaptive behavioral responses need to
be engaged (eg,approach a reward or avoid a stress);(ii)
once the behavioral response is established, dopamine
release is antecedent to the appearance of the motiva-
tionally relevant event and is triggered by environmental
associations that the organism has made with the event as
part of learning the adaptive behavioral response.In this
way, dopamine serves to alert and thereby prepare the
organism for an impending important event.
The primary differences between psychostimulant-induced
dopamine release and release associated with normal
learning about important environmental events such as
rewards and stressors is:(i) since psychostimulants block
the elimination of dopamine through DAT, the level of
dopamine achieved far exceeds what is possible from a
biological stimulus;(ii) in contrast to biological stimuli that
cease to release dopamine once an approach or avoidance
response to that stimulus has been learned,psychostimu-
lants continue to release large amounts of dopamine upon
every administration (with the possible exception of
extended binging that can temporarily deplete dopamine
stores).
27Thus,with psychostimulants,each administration
releases dopamine into mesocorticolimbic regions,caus-
ing further associations to be made between the drug
experience and the environment.In this way,it is thought
that the more a psychostimulant is administered,the more
learned associations are made with the environment and
the more effective the environment becomes at triggering
craving and drug-seeking.It is this “overlearning”of drug-
seeking behaviors by progressive associations formed
between repeated drug-induced dopamine release and the
environment that is thought to lead to increased vulnera-
bility to relapse.
How psychostimulant-induced dopamine
release creates pathological neuroplasticity 
in cortical regulation of behavior
As outlined above,psychostimulant-induced dopamine
release  is responsible for reinforcing behaviors designed
to seek and administer the drugs.The dopamine projec-
tions involved in this process are outlined in Figure 1A,
and as indicated, the most critical projection in this
regard is the projection from the ventral tegmental area
dopamine cells to the nucleus accumbens.
28-31 For exam-
ple,if psychostimulant-induced release of dopamine in
the nucleus accumbens is impaired,this affects the acqui-
sition of drug-seeking behaviors,and can markedly influ-
ence the amount of drug taken in a well-trained subject.
Thus, the learning of a task to obtain the drug and the
amount of drug taken in a given session is strongly regu-
lated by dopamine release in the accumbens.However,
when an animal has been withdrawn from repeated psy-
chostimulant use, and drug-seeking is initiated by an
environmental stimulus such as a cue previously paired
with drug delivery, or a novel stressor, it is dopamine
release in the prefrontal cortex and amygdala, respec-
tively,that mediates the reinstatement of drug-seeking.
32,33
Thus,relapse can be induced by dopamine release in pre-
frontal and allocortical brain regions, and reflects the
aforementioned physiological role of dopamine release
as a predictive antecendent to stimulus (drug) delivery.
What this implies is that chronic release of dopamine by
repeated psychostimulant administration may be modi-
fying cortical and allocortical regulation of behavior.
Figure 1B shows that the cortical and allocortical regu-
lation of behavior is primarily mediated by glutamater-
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Figure 1. Models of the circuitry regulating the transition from psychos-
timulant reward to relapse. 
A. Dopamine projections and how chronic psychostimulant use
produces a transition from reliance on accumbens dopamine for
drug reinforcement, to reliance on the prefrontal and amygala
dopamine to trigger relapse, to dopamine in the caudate in reg-
ulating habit responding. B. The circuitry in which dopamine
projections are embedded that initiates relapse to drug-taking.
Note that dopamine input to the amygdala and prefrontal cor-
tex is critical, as is the glutamatergic output from these regions
to the nucleus accumbens. GABA, γ-aminobutyric acidgic projections.These projections are to subcortical struc-
tures,such as the nucleus accumbens and dopamine cells
in the ventral tegmental area,as well as between the cor-
tical and allocortical regions. Thus, when dopamine is
released into the prefrontal cortex or amygdala by a
drug-associated cue or stressor,this is thought to stimu-
late glutamatergic projections between the prefrontal
cortex and amygdala,as well as glutamatergic outputs to
the accumbens and ventral tegmental area.
34A variety of
studies have linked this activation of corticofugal gluta-
mate transmission with craving in psychostimulant
addicts or drug-seeking in animal models of addiction.
The neuroimaging literature clearly shows metabolic acti-
vation of regions of the prefrontal cortex,including por-
tions of the anterior cingulate and ventral orbital cortices,
and the amygdala during cue-induced craving for
amphetamine-like psychostimulants.
35-39 Interestingly,
while a cue or low dose of psychostimlant markedly
increases metabolic activity in the prefrontal cortex and
amygdala,in the absence of a learned drug association
the prefrontal cortex is hypoactive.
40 The reduction in
basal metabolic activity is taken to indicate a potential
deficit in cognitive ability to regulate relapse,and recent
cognitive testing in psychostimulant addicts confirms the
presence of certain cognitive dysfunctions related to
impulse control and switching behaviors in an adaptive
manner to changing environmental circumstances.
41-45A
strong role for activation of both the prefrontal cortex
and amygdala has been confirmed in animal studies.
Thus, pharmacological inhibition of either of these
regions prevents the reinstatement of drug-seeking in
animals withdrawn from drugs that have undergone
extinction training.
46-48 Moreover,a marked release of glu-
tamate is measured in the nucleus accumbens of animals
initiating drug-seeking in response to a stressor,and this
glutamate is derived from increased activity in the pro-
jection from the prefrontal cortex to the nucleus accum-
bens.
49,50Accordingly,drug-seeking is abolished by inhibit-
ing glutamate receptors in the accumbens.
51-53
One final set of studies to be considered regarding corti-
cal glutamate is the recent evidence that as drug-seeking
becomes more compulsive there is a gradual shift to
greater reliance on corticostriatal habit circuitry,and less
involvement of prefrontal to accumbens circuitry.
54This
possibility is supported by animal models in two ways:(i)
if animals that have been trained to self-administer
cocaine are left in abstinence for an extended period,
drug-seeking is augmented,
55 and in this case inhibition
of the prefrontal cortex or amygdala no longer inhibits
drug-seeking induced by drug-associated stimuli.
However,inhibition of the dorsolateral striatum is still
effective at blocking drug-seeking
56;(ii) as training of an
animal in drug-seeking paradigms progresses it is possi-
ble to show a gradual increase in dopamine released into
the caudate in favor of release into the nucleus accum-
bens.
57 This is illustrated in Figure 1A, showing that
dopamine release into the caudate can regulate habitual
behaviors.On one hand,these data point to the possibil-
ity that in treating compulsive relapse we should be
focusing on regulation of corticostriatal habit circuitry,
including glutamate input to the caudate from sensory-
motor cortex and dopamine input from the substantia
nigra. However, these studies have been conducted in
rats in whom the frontal cortex is poorly evolved, and
given the marked activation produced in the prefrontal
cortex and amygdala by drug-associated stimuli in psy-
chostimulant addicts, the conclusion that compulsive
relapse is entirely derived from corticostriatal habit cir-
cuitry may be an oversimplification.Indeed,it has been
argued that a primary role for therapy in treating addic-
tion is to strengthen prefrontal regulation of drug-seek-
ing behaviors,whether through psychosocial interven-
tions or pharmacotherapy.
27,58,59
Enduring psychostimulant-induced 
neuroplasticity in the prefrontal to 
accumbens glutamate projection
Given the apparent critical role played by glutamatergic
afferents to the nucleus accumbens in initiating drug-
seeking or craving,recent studies have identified a num-
ber of enduring cellular changes in glutamate transmis-
sion that may be critical pathological neuroadaptations
to psychostimulant use, and may serve as targets for
pharmcotherapeutic intervention.In general the neuro-
plasticity can be categorized as postsynaptic,presynaptic
and nonsynaptic (ie, residing predominantly in glia).
However,since these processes are intimately related to
each other,it is perhaps best to consider all the adapta-
tions as changes in glutamate homeostasis,the end result
of which is a psychostimulant-induced enduring change
in the fidelity of communication between the prefrontal
cortex and the nucleus accumbens,and the regulation by
this projection of corticostriatal habit circuitry. It has
been proposed that this loss of fidelity results in a weak-
ening or loss in the capacity of psychostimulant addicts
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making drug-seeking more difficult to control and
increasing the vulnerability to relapse.
27
As mentioned above,drug-seeking is associated with a
large release of prefrontal glutamate into the nucleus
accumbens.The large release of glutamate during drug-
seeking is all the more remarkable because it was dis-
covered using microdialysis.which is not a very sensitive
measure of glutamate transmission.
60 Indeed,when ani-
mals are trained to seek a biological reward,such as food,
microdialysis cannot measure glutamate release.
49Thus,
the large psychostimulant-induced release of glutamate
has been hypothesized to be a pathological and perhaps
critical mediator of relapse.This hypothesis is supported
by the fact that treatments interrupting synaptic gluta-
mate release also inhibit drug-seeking.This includes a
variety of pharmacological treatments that have the
potential to be developed into pharmacotherapeutic
agents,as outlined below.
Perhaps in part a consequence of the massive synaptic
glutamate release occurring during psychostimulant-
seeking behavior,a number of marked changes in post-
synaptic glutamate transmission have been measured in
animals withdrawn from chronic cocaine or ampheta-
mine administration.Perhaps among the most dramatic
is an increase in the density of dendritic spines in the
nucleus accumbens.
61 Importantly, this appears to be
accompanied by an increase in the insertion of α-amino-
3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)
glutamate receptors into the membrane of spiny neurons
in the accumbens,
62 and is associated with an increase in
electrophysiological sensitivity to AMPA receptor stim-
ulation (as measured by the AMPA:N-methyl D-aspar-
tate [NMDA] ratio).
63 Moreover,a number of other pro-
teins regulating the fidelity of postsynaptic glutamate
transmission are altered after chronic cocaine use,includ-
ing proteins that regulate the structure and function of
the protein scaffolding in which the glutamate receptors
are embedded,including postsynaptic density (PSD)-95
and Homer proteins,among others.
64,65Also,in addition
to AMPA ionotropic glutamate receptors, signaling
through metabotropic glutamate receptors is downregu-
lated.
66,67 Finally, this psychostimulant-induced postsy-
naptic neuroplasticity is associated with changes in the
biochemical machinery regulating spine formation,
notably an increase in actin cycling and formation of F-
actin (a primary structural protein regulating spine mor-
phology and the insertion of proteins into and out of the
membrane).
68Taken together,these findings indicate that
significant changes have been produced by psychostim-
ulants in the way that synaptically released glutamate will
be interpreted by postsynaptic cells.However,it is impor-
tant to note that this knowledge is nascent and emerging.
Thus,there remain many apparent contradictions in the
literature regarding changes in specific proteins,and in
the overall direction of synaptic grading (ie, is postsy-
naptic glutamate transmission augmented or inhibited by
chronic psychostimulant administration).
69Therefore,for
now it is probably not prudent to speculate on the type
of drug development that may arise from this particular
direction of research into psychostimulant-induced
changes in glutamate signaling.
Ideas for pharmacotherapies based upon 
psychostimulant-induced plasticity in 
glutamate transmission
As outlined above,given our current state of knowledge
it is more likely that pharmacotherapeutic restoration of
normal glutamate release may be a more successful
approach than manipulating postsynaptic proteins respon-
sible for and/or associated with changes in the fidelity of
postsynaptic glutamate transmission.In part,this is due to
the relatively contradictory status of the emerging litera-
ture on postsynaptic plasticity. Moreover, it has been
hypothesized that the adaptations in presynaptic gluta-
mate release may be at least partly causal in the postsy-
naptic adaptations,posing the possibility that if the patho-
logical release of glutamate can be successfully
ameliorated,postsynaptic normalization may follow.
27
Pharmacotherapeutic targets for regulating the patho-
logical synaptic glutamate release seen in the accumbens
of psychostimulant-seeking animals can be placed into
two categories:(i) targets based upon psychostimulant
induced changes in proteins regulating synaptic gluta-
mate release; (ii) proteins that produce a general
decrease in excitatory transmission.Compounds in the
first category are likely to be the most specific for psy-
chostimulant addiction,and perhaps carry the least num-
ber of unwanted side effects, while the latter category
may be less selective not only regarding effects on other
addictive drugs, but also in terms of unwanted side
effects.Table I lists some potential pharmacotherapeutic
targets according to these two categories.
Neuroplasticity produced by chronic cocaine adminis-
tration that could potentially contribute to pathological
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tamate exchange, downregulation of glial glutamate
transporters,and downregulation of release-regulating
presynaptic metabotropic glutamate receptors
(mGluR2/3).Importantly,these three changes are inter-
related due to the cystine-glutamate exchanger and glu-
tamate transporter regulating extrasynaptic glutamate
tone on release regulating mGluR2/3.
70,71 Drugs have
been examined in animal models of psychostimulant
addiction, and to a lesser extent in clinical trials with
cocaine addicts that regulate one or more of these
processes.For example,N-acetylcysteine upregulates cys-
tine glutamate exchange,and has been shown in animal
models to prevent synaptic glutamate release associated
with drug-seeking, restore inhibitory tone on synaptic
release through activation of mGluR2/3,and to inhibit
the desire for cocaine in a double-blind cue-reactivity
trial in non-treatment-seeking cocaine addicts.
71-73Also,
mGluR2/3 agonists have proven effective at inhibiting
cocaine seeking in animal models; however, unlike N-
acetylcysteine,food-seeking was inhibited at only a 3- to
10-fold increase in dose relative to inhibiting cocaine-
seeking.
74,75Although no studies have yet evaluated reg-
ulating glutamate transport in drug-seeking models of
psychostimulant addiction,recent reports of the use of β-
lactam antibiotics to increase glutamate transporter
membrane insertion poses an interesting possibility for
pharmacologically overcoming the cocaine-induced
downregulation of glutamate transporters.Finally,while
the mechanism is not clear,modafinil has been reported
to increase extracellular glutamate levels,which would
restore tone on release inhibiting mGluR2/3.
76 Notably,
modafinil has been found to successfully decrease
cocaine relapse in a number of clinical trials.
77,78
The primary drugs in the category of nonspecific
inhibitors of synaptic glutamate release include a variety
of γ-aminobutyric acid (GABA)-mimetic compounds.
These range from relatively specific agonists at GABAb
receptors,such as baclofen,which inhibit synaptic gluta-
mate release to a host of less selective compounds known
to increase GABA transmission via interactions with syn-
thetic or elimination mechanisms,such as topiramate or
vigabatrin.For all of these compounds there is preclini-
cal and clinical data to support some potential efficacy.
79-
85 However,as predicted,especially for the nonselective
GABAmimetics untoward side effects,such as sedation,
are reported.
Conclusions
This review has endeavored to transport the reader from
the initiating molecular actions of amphetamine-like psy-
chostimulants on dopamine systems in the brain to
enduring neuroplasticity produced in glutamate trans-
mission responsible for communicating from prefrontal
and allocortical brain regions through the nucleus accum-
bens to motor regulatory systems.Moreover,by examin-
ing molecular neuroplasticity produced in excitatory
synapses by chronic psychostimulant administration,it is
possible to make some deductions about potential phar-
macotherapeutic interventions. Indeed, there already
exists an emerging literature supporting this approach in
developing potential pharmacotherapies for treating psy-
chostimulant addiction.Importantly,this is a nascent and
emerging science,and while much has been discovered,
the cutting edge of discovery into the neuroplasticity pro-
duced by psychostimulants is understandably contradic-
tory. As further discoveries are made that allow us to
understand the nature of these contradictions,it should
follow that additional targets will emerge to provide
potential novel pharmacotherapies for treating psychos-
timulant addiction. ❏
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Table I. List of compounds that affect glutamate neurotransmission with potential pharmacotherapeutic value in treating addiction to ampheta-
mine-like psychostimulants. mGluR2/3, metabotropic glutamate receptors; GABA, γ-aminobutyric acid; AMPA, α-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid
Directly reducing glutamate transmission Indirectly inhibiting glutamate transmission
Compound Target Compound Target
N-acetylcysteine Cystine/glutamate exchanger Baclofen GABA-b receptor
β-lactam Glutamate transporter Topiramate GABA-a and AMPA
mGluR2/3 agonist mGluR2/3 Vigabatrin GABA transaminase
Modafinil mGluR2/3395
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Cocaína y psicoestimulantes tipo 
anfetamina: circuitos neuronales y 
neuroplasticidad glutamatérgica
Aunque es bien conocida la farmacología de los psi-
coestimulantes tipo anfetamina a nivel de los trans-
portadores de dopamina, ha sido difícil abordar la
adicción a esta clase de drogas. La razón de esta dis-
cordancia se explica porque si bien el mecanismo
molecular de la acción de la anfetamina es crítico
para reforzar el uso de la droga, éste representa
sólo el primer paso en una secuencia de numerosos
acontecimientos neuroplásticos en los circuitos cere-
brales. Esta revisión resume el efecto de los psico-
estimulantes en las proyecciones mesocorticolímbi-
cas de dopamina que median el efecto de refuerzo,
y cómo esta acción en último término conduce a
una neuroplasticidad patológica permanente en las
proyecciones glutamatérgicas desde la corteza pre-
frontal hasta el núcleo accumbens. Se describen las
neuroadaptaciones moleculares inducidas por el
abuso de psicoestimulantes en la neurotransmisión
glutamatérgica, y a partir de esta información se
identifican potenciales blancos farmacoterapéuti-
cos, en base a las modificaciones en la neuroplas-
ticidad inducida por psicoestimulantes.  
Cocaïne et psychostimulants 
amphétaminoïdes : circuits neuronaux et 
neuroplasticité du glutamate
En dépit d’une bonne compréhension  de la phar-
macologie des psychostimulants amphétaminoïdes
au niveau des transporteurs de la dopamine, il
semble difficile  de faire face à l’addiction à cette
classe de médicaments. Cette discordance s’explique
ainsi : si le mécanisme moléculaire de l’action amphé-
taminique est essentiel pour renforcer l’action du
médicament, il ne représente  qu’une première
étape dans une succession de nombreux événements
neuroplastiques dans le circuit cérébral. Cette revue
souligne l’effet des psychostimulants sur les projec-
tions méso-cortico-limbiques dopaminergiques qui
médient  l’effet de consolidation et explique com-
ment cette action mène finalement à une neuro-
plasticité pathologique persistante dans les projec-
tions glutamatergiques, du cortex préfrontal au
noyau accumbens. Les neuroadaptations molécu-
laires induites par l’abus des psychostimulants sont
décrites en ce qui concerne la  neurotransmission du
glutamate, et des cibles pharmacothérapeutiques
potentielles sont  identifiées à partir de ces informa-
tions, basées sur la neuroplasticité réversible ou
annulable induite par les psychostimulants.
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